

GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION

UPDATED VERSION
APRIL 2016

GUIDELINES



GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION

UPDATED VERSION
APRIL 2016

GUIDELINES

WHO Library Cataloguing-in-Publication Data

Guidelines for the screening care and treatment of persons with chronic hepatitis C infection.
Updated version, April 2016

I. World Health Organization.

ISBN 978 92 4 154961 5

Subject headings are available from WHO institutional repository

© World Health Organization 2016

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland

Design and layout: blossoming.it

CONTENTS

ACKNOWLEDGEMENTS	5
ABBREVIATIONS AND ACRONYMS	8
GLOSSARY OF TERMS	10
EXECUTIVE SUMMARY	11
1. SCOPE AND OBJECTIVES	16
1.1 Target audience	16
1.2 Scope of the guidelines	17
1.3 Related guidelines	17
2. BACKGROUND	18
2.1 Epidemiology	18
2.2 Screening for HCV infection	27
2.3 Care of patients with HCV infection	27
2.4 Treatment of HCV infection	27
2.5 Access to and price of direct-acting antivirals	30
3. GUIDING PRINCIPLES	32
3.1 Human rights	32
3.2 Access to health care	32
3.3 Service provision	32
3.4 Integrated health care	33
3.5 Public health approach	33
4. METHODS	34
4.1 Updating the existing guidelines	34
4.2 WHO guideline development process	34
4.3 Formulation of recommendations	35
4.4 Roles	36
4.5 Declarations of interest	37
4.6 Evidence that informed the recommendations	37
5. RECOMMENDATIONS ON SCREENING	43
5.1 Screening to identify persons with HCV infection	43
5.2 When to confirm a diagnosis of chronic HCV infection	47
6. RECOMMENDATIONS ON CARE OF PEOPLE INFECTED WITH HCV	50
6.1 Screening for alcohol use and counselling to reduce moderate and high levels of alcohol intake	50
6.2 Assessing the degree of liver fibrosis and cirrhosis	54

7. RECOMMENDATIONS ON TREATMENT	59
7.1 Assessment for HCV treatment	59
7.2 Treatment with direct-acting antiviral agents	62
7.3 Removal of recommendation for treatment with telaprevir or boceprevir	69
7.4 Preferred and alternative regimens for the treatment of persons with chronic hepatitis C virus infection	71
7.5 Treatment with pegylated interferon and ribavirin	78
8. CLINICAL CONSIDERATIONS	81
8.1 Clinical assessment of patients prior to treatment	82
8.2 Monitoring for adverse events	84
8.3 Drug–drug interactions	88
8.4 Monitoring for treatment response	90
9. SPECIAL CONSIDERATIONS FOR SPECIFIC POPULATIONS	92
9.1 People who inject drugs	92
9.2 Persons with HIV/HCV coinfection	94
9.3 Children and adolescents	96
9.4 Persons with cirrhosis	97
9.5 Persons with chronic kidney disease	98
9.6 Persons with HBV/HCV coinfection	98
9.7 Persons with TB/HCV coinfection	99
10. OPERATIONAL AND IMPLEMENTATION ISSUES	100
10.1 Factors to be considered in prioritizing who receives treatment	101
10.2 Service planning	105
10.3 Service delivery	106
10.4 Concerns of infringement of patient rights due to implementation of anti-diversion measures	106
11. DISSEMINATION AND UPDATING OF THE GUIDELINES	108
REFERENCES	109

Web Appendices, 2016

All appendices are made available on the WHO hepatitis website.

Appendix 1: PICO questions

Appendix 2: Network meta-analysis report

Appendix 3: Budget impact analysis

Appendix 4: Values and preferences

Appendix 5: Decision-making tables

Appendix 6: Summary of declared interests

Appendix 7: Data from observational cohorts

Web Appendices for the 2014 version of this guideline is available at:

<http://who.int/hepatitis/publications/hepatitis-c-guidelines/en/>

ACKNOWLEDGEMENTS

Many professionals from a range of backgrounds and specialties have contributed to the development of this guidance. WHO is sincerely grateful for their time and support.

Guidelines Development Group

2016 Recommendations

The chair of the Guidelines Development Group was Saeed Sadiq Hamid (The Aga Khan University & Hospital, Pakistan). Roger Chou (Oregon Health & Science University, USA) was the guideline methodologist.

The following experts served on the Guidelines Development Group:

Isabelle Andrieux-Meyer (Médecins Sans Frontières, Switzerland); Evaldo Stanislaw Affonso Araújo (University of São Paulo Hospital das Clínicas Infectious Diseases, Brazil); Manal Hamdy El-Sayed (Ain Shams University, Egypt); Charles Gore (World Hepatitis Alliance, Switzerland); Giten Khwairakpam (TREAT Asia/amFAR, Thailand); Karine Lacombe (Hôpital Saint-Antoine, Sorbonne-Universités, France); Olufunmilayo Lesi (University of Lagos, Nigeria); Niklas Luhmann (Médecins du Monde, France); Francesco Negro (Geneva University Hospitals, Switzerland); David R. Nelson (University of Florida, USA); Ponsiano Ocama (Makerere University, Uganda); Baatarkhuu Oidov (Mongolian National University of Medical Sciences, Mongolia); Jürgen Rockstroh (University of Bonn, Germany); Tracy Swan (Treatment Action Group, USA); Lynn E. Taylor (The Warren Alpert Medical School of Brown University, USA); Emma Thomson (University of Glasgow, UK); Lai Wei (Peking University Health Science Center, China).

2014 Recommendations

The chairs of the Guidelines Development Group were Bryce Smith (Centers for Disease Control and Prevention, USA) and Yngve Falck-Ytter (Case Western Reserve University, USA). Rebecca Morgan (Centers for Disease Control and Prevention, USA) and Yngve Falck-Ytter were the guideline methodologists.

The following experts served on the Guidelines Development Group:

Isabelle Andrieux-Meyer (Médecins sans Frontières, Switzerland); Ruth Birgin (Women and Harm Reduction International Network, Australia); Scott Bowden (Victorian Infectious Diseases Reference Laboratory, Australia); Vladimir Chulanov (Central Research Institute of Epidemiology, Reference Center for Viral Hepatitis, Russia); Wahid Doss (National Hepatology and Tropical Medicine Research Institute, Egypt); Nicolas Durier (TREAT Asia/amFAR – Foundation for AIDS Research, Thailand); Serge Paul Eholie (Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Treichville, Côte

d'Ivoire); Manal Hamdy El-Sayed (Faculty of Medicine, Ain Shams University, Egypt); Jorge Enrique González (National Reference Laboratory, Argentina); Charles Gore (World Hepatitis Alliance, Switzerland); Koji Ishii (National Institute of Infectious Diseases, Japan); S. M. Wasim Jafri (The Aga Khan University, Pakistan); Maud Lemoine (Medical Research Council, The Gambia Unit, Imperial College London, United Kingdom [UK]); Anna Lok (University of Michigan and American Association for the Study of Liver Diseases, USA); Endale Kassa Lulu (Addis Ababa University, Ethiopia); Nahum Méndez-Sánchez (Medica Sur Clinic & Foundation, Mexico); Shiv Kumar Sarin (Institute of Liver and Biliary Sciences, India); Masashi Mizokami (National Institute of Infectious Diseases, Japan); Dasha Ocheret (Eurasian Harm Reduction Network, Lithuania); Frederick Okoth (Kenya Medical Research Institute, Kenya); John Parry (Public Health England, UK); Umesh Sharma (Asian Network of People who Use Drugs, India/Australia); Bernd Stalenkrantz (International Network of People who Use Drugs, Sweden); Tracy Swan (Treatment Action Group, USA); Lynn E. Taylor (The Warren Alpert Medical School of Brown University, USA); Xiaochun Wang (National Centre for AIDS/STD Prevention and Control, China).

External peer review group

The following experts served as external peer reviewers of the draft guidelines documents:

Jude Byrne (Australian Injecting & Illicit Drug Users League, Australia); Vladimir Chulanov (Central Research Institute of Epidemiology, Russia); Curtis Cooper (University of Ottawa, Canada); Graham Cooke (Imperial College London, UK); Marc Ghany (National Institutes of Health, USA); Jorge Enrique Gonzalez (National Reference Laboratory, Argentina); Sharon Hutchinson (Health Protection Scotland, UK); Wasim Jafri (Aga Khan University, Pakistan); Endale Kassa (Addis Ababa University, Ethiopia); Ahmed Khatib (Ministry of Health and Social Welfare, Zanzibar, Tanzania); Anna Lok (University of Michigan, USA); Pauline Londeix (Act Up-Basel, Europe); Ludmila Maistat (Alliance for Public Health, Ukraine); Nahum Mendez-Sanchez (Medica Sur Clinic and Foundation, Mexico); Mojca Maticic (University Medical Centre Ljubljana, Slovenia); Frederick Okoth (Kenya Medical Research Institute, Kenya); Lars Peters (University of Copenhagen, Denmark); Shiv Kumar Sarin (Institute of Liver and Biliary Sciences, India); Mark Thursz (Imperial College, UK); Emmanouil Tsochatzis (Royal Free Hospital and University College London Institute of Liver and Digestive Health, UK); Imam Waked (National Liver Institute, Egypt); Takaji Wakita (National Institute of Infectious Diseases, Japan); Yazdan Yazdanpanah (Hopital Richet Claude Bernard, France).

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27045

